Quantcast
Last updated on April 24, 2014 at 16:01 EDT

Aeterna Zentaris: Posters to be Presented on Phase 1 and Phase 2 Trials with AEZS-108 in Prostate and Breast Cancer at Upcoming ASCO Meeting

May 23, 2013

QUÉBEC CITY, May 23, 2013 /PRNewswire/ – Aeterna Zentaris Inc. (NASDAQ:
AEZS) (TSX: AEZ) (the ”Company”) today announced that the following
posters will be presented on AEZS-108, the Company’s lead oncology
compound, at the upcoming American Society of Clinical Oncology
(“ASCO”) annual meeting, which will be held May 31 to June 4, 2013, in
Chicago.


    Abstract # 5062:  "A Phase 1 Dose Escalating Trial of AEZS-108 in
                      Taxane- and Castration-Resistant Prostate Cancer", J.
                      Pinski, A.V. Schally, D. Tsao-Wei, T.B. Dorff, S.
                      Groshen, S. Xiong, D. Quinn, Y. Tai, J. Engel, S.V.
                      Liu.

    Presenter:        Jacek Pinski, MD, PhD, USC Norris Comprehensive
                      Cancer Center, California

    Date & Time:      Monday, June 3, 2013, from 8:00 am to 11:45 am
                      (central)

    Venue:            SHall 2, McCormick Place, Chicago


    Abstract # TPS 11124:  "A Randomized Phase 2 Trial of AEZS-108 in
                           Chemotherapy Refractory Triple-Negative
                           (ER/PR/HER2-Negative) LHRH-R Positive Metastatic
                           Breast Cancer", S. Buchholz, J.B. Engel, A.V.
                           Schally, S. Seitz, O. Ortmann, G. Emons, R.L.
                           Mahtani, S. Glück, C. Vogel, A.J. Montero.

    Presenter:             Stefan Buchholz, MD, Medical Center University
                           of Regensburg, Germany

    Date & Time:           Monday, June 3, 2013, from 1:15 pm to 5:00 pm
                           (central)

    Venue:                 S Hall 2, McCormick Place, Chicago

A third abstract (# e15596) on AEZS-108, “A Case Report of a Long-Term Response in a Patient with Urothelial
Cancer (UC) Treated with AEZS-108
“, G. L. Fernandez, A. V. Schally, T. Koru-Sengul, M. Jorda, J. R.
Merchan, A. M. Flores, N. L. Block, M. Manoharan, J. Engel, is
currently available online on ASCO’s website, but will not be presented during a poster session. The abstract
reports on the first patient with LHRH-R positive UC treated with
AEZS-108 in an ongoing Phase 1 clinical trial.

About AEZS-108 (doxorubicin peptide conjugate)

AEZS-108 represents a new targeting concept in oncology using a hybrid
molecule composed of a synthetic peptide carrier and a well-known
chemotherapy agent, doxorubicin. AEZS-108 is the first intravenous drug
in advanced clinical development that directs the chemotherapy agent
specifically to LHRH-receptor expressing tumors, resulting in more
targeted treatment with less damage to healthy tissue. The product has
successfully completed Phase 2 studies for the treatment of ovarian and
endometrial cancer and the Company is currently initiating a Phase 3
trial in endometrial cancer under a Special Protocol Assessment.
AEZS-108 is also in Phase 2 trials in triple-negative breast cancer,
prostate cancer and bladder cancer. AEZS-108 has been granted orphan
drug designation by the FDA and orphan medicinal product designation
from the European Medicines Agency for the treatment of ovarian cancer.
Aeterna Zentaris owns worldwide rights to AEZS-108.

About Aeterna Zentaris

Aeterna Zentaris is an oncology and endocrinology drug development
company currently investigating treatments for various unmet medical
needs. The Company’s pipeline encompasses compounds at all stages of
development, from drug discovery through to marketed products. For more
information, visit www.aezsinc.com.

 

SOURCE Aeterna Zentaris Inc.


Source: PR Newswire